The Food and Drug Administration on Friday approved updated labeling for three more menopausal hormone therapy products, removing outdated statements about cardiovascular disease, breast cancer and probable dementia from the boxed warnings — the strongest warnings on a drug label — so that the labels now reflect what the agency calls current science.
The three products are estradiol patches worn on the skin, and the approvals follow the same change the FDA made for six other hormone therapy products in February. Friday's step continues a process the agency began in November 2025, when it asked drug companies to submit revised labels; 29 companies have since sent in proposed changes, and the FDA says it is working through them.
"Removing outdated statements from these boxed warnings marks a major victory for women's health," said Health and Human Services Secretary Robert F. Kennedy Jr. "Under President Trump's leadership, we are changing how the federal government approaches menopause care. We are updating labels to reflect current science, confronting barriers to treatment, and working with manufacturers to expand supply."
For women, the change is practical. The FDA itself says the old warning language had cautioned women away from treatments they might otherwise have chosen with their doctors. With the outdated statements gone, the decision goes back to a woman and her doctor, based on the therapy's actual benefit-risk profile as the agency now states it — not on warnings the government itself has concluded no longer hold up against the scientific literature it re-examined.
The administration moved on supply at the same time, expecting demand to rise as women who had been scared off come back. The FDA says it is in close contact with the makers of every approved menopausal hormone therapy and is working with all six manufacturers of estradiol patches, which have added production capacity and extra shifts — doubling overall patch output in the last 12 months. The agency says it is not aware of any imminent risk of a nationwide shortage, and it has kept compounding channels open so pharmacies can keep meeting individual patients' needs while factory output catches up.
The FDA is also working with drug sponsors to explore making vaginal estrogen products available over the counter, without a prescription. Any such switch would still need the agency's approval, on evidence that women can choose and use the products safely on their own — but it would remove one more trip to the doctor's office standing between a woman and a treatment.
Friday's action carries out President Trump's executive order "Advancing Women's Health to Improve Outcomes in All Phases of Life," signed on October 19. The order and its task force came out of First Lady Melania Trump's Women's Health Innovation platform. "Now is the time for America's resources to focus on girls and women," the First Lady said. "Through my Women's Health Innovation platform, we will accelerate innovation and common-sense partnerships with the private sector to benefit America's women."
"FDA's actions today are grounded in, and consistent with, a sustained commitment to women's health as a cross-cutting agency priority," said Acting FDA Commissioner Kyle Diamantas. "We are equally committed to ensuring that when women and their doctors determine hormone therapy is right for them, they can access it. That means advancing both the most up-to-date labeling and access to treatment." CMS Administrator Dr. Mehmet Oz called the announcement "an important step forward in supporting women's health."
📰 ProfiloPolitics Member News — choose your news, share it, earn credit
Members choose the news they want — share it and earn credit.
📣 Join ProfiloPolitics on Telegram — breaking news first
Follow @profilopoliticsnews for every update on this story.